☆ 3.8 Meeting Abstract

BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer

Rate this paper

Find Funding. Review Successful Grants.

Become a Peeref-certified reviewer

Export Citation

Share Paper